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Abstract
Background: Clinical studies for testing new drugs against hepatitis B ought to be carried out in
low prevalence areas despite difficulties on patient recruitment. In such areas, relatives of chronic
hepatitis B patients are considered to be at risk of acquiring the hepatitis B virus (HBV). The aim
of this study was to evaluate the prevalence of HBV markers (anti-HBc, HBsAg and anti-HBs) in
familial members of chronic hepatitis B (CHB) patients according to their origin (Asian or Western)
in a low prevalence area, the city of São Paulo, Brazil.
Methods: Twenty three Asian CHB probands and their 313 relatives plus 31 CHB probands of
Western origin and their 211 relatives were screened for HBV serological markers; the study was
carried out in the outpatient clinic of the University of São Paulo School of Medicine.
Results: Mother to child transmission was greater in the Asian group whereas sexual transmission
was more frequent in the Western group (p < 0.0001). Anti-HBc was positive in 90% and 57% of
the Asian and Western parents (p = 0.0432) and in 97% and 33% of the Asian and Western
brothers (p = 0.0001), respectively. HBsAg was more frequent among the Asian (66%) than the
Western (15%) mothers (p = 0.0260) as well as among the Asian (81%) than the Western (19%)
brothers (p = 0.0001). We could detect 110 new HBsAg-positive subjects related to the 54 index
patients, being the majority (81%) of Asian origin.
Conclusion: In low prevalence area of hepatitis B, family members and household contacts of
chronic HBV carriers are at high risk for acquiring hepatitis B.
Background
Hepatitis B virus (HBV) infection is a major health prob-
lem. Of the 2 billion people who have been infected with
the hepatitis B virus (HBV), more than 350 million have
chronic (lifelong) infections. These chronically infected
persons are at high risk of death from cirrhosis of the liver
and liver cancer, diseases that kill about one million per-
sons each year. Treatment with antiviral drugs can slow
the progression of the liver disease to cirrhosis and thus
avoid or delay the necessity of liver transplantation.
Therefore, early hepatitis B diagnosis could benefit many
asymptomatic patients.
In the last decade new antiviral drugs for hepatitis B have
emerged and revolutionized the treatment of its chronic
from. Lamivudine is a nucleoside reverse transcriptase
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inhibitor and is currently used in many countries for the
hepatitis B treatment. Despite the potent action of this
drug, the development of viral resistance prompted the
search for new therapeutic agents and new strategies to
treat hepatitis B [1]. Adefovir is a new nucleoside analogue
that has shown to be effective in cases of lamivudine-
resistant virus [2-4]. Even considering these data, the
report of an HBV variant resistant to adefovir [5] adds
weight to the need for developing new therapies to treat
CHB. To this end, several clinical trials with monotherapy
and drug-combination regimens are in progress world-
wide [6].
A critical step of the drug approval process is patient
recruitment, comprising 25% of the time of clinical trials.
To expedite the approval process of anti-HBV drugs, there
is a growing interest in clinical trials in Latin America and
other HBV emerging regions. In Brazil, the prevalence of
HBsAg varies greatly through out its large territory – being
high at the Amazon basin, medium at the northeast and
low at the southeast and south regions of the country [7].
Although the prevalence of HBsAg is low in blood donors
(0.36%) of the low prevalence area of São Paulo, among
risk groups for HBV infection in the same city, HBsAg
prevalence can be very high.
The aim of the present study was to evaluate the preva-
lence of HBV markers (anti-HBc, HBsAg and anti-HBs) in
family members of patients with chronic hepatitis B – in
a low prevalence area – according to their origin, Western
or Asian.
Methods
All study procedures were approved by the institutional
review board of the Department of Gastroenterology of
the University of SãoPaulo School of Medicine, São Paulo.
Patients
The prospective surveillance program in relatives of
patients with chronic hepatitis B (CHB) comprised clini-
cal assessment and serological screening. The criterion for
proband (index case) inclusion in the cohort was being a
chronic hepatitis B carrier, defined by HBsAg positivity for
longer than 6 months. The exclusion criteria were: hepati-
tis C infection, hepatitits D infection or history of alcohol-
ism. Using these criteria, a total of 54 out of 59
consecutive patients with chronic hepatitis seen in our
Department could be included. Of these CHB index cases,
23 were identified as Asian descendent (Japanese or Chi-
nese) and 31 as Westerns. All family members of the
probands were tested for HBV serological markers: 211
and 313 relatives of the oriental and occidental origin,
respectively.
Mode of HBV transmission
The mode of HBV transmission was classified by the fol-
lowing clinical and serologic criteria:
a) Probably mother to child: (i) when mother presented
anti-HBc and anti-HBs positive and familial history of
hepatitis B-related diseases or (ii) in the absence of sero-
logic history of hepatitis B-related diseases in the family;
b) Mother to child: when the mother was (i) HBsAg posi-
tive or (ii) deceased due to HBV-related hepatitis, liver cir-
rhosis or hepatocellular carcinoma or (iii) the mother
presented history of acute hepatitis B near partum;
c) Sexual (horizontal): (i) when mother presented anti-
HBc and anti-HBs negative or anti-HBs positive due to
vaccination or (ii) absence of familial history of HBV-
related liver diseases and the subject presented risk factors
for contamination (e.g.: drug user, promiscuity, blood
transfusion) or (iii) spouse positive for HBsAg or (iv)
absence of familial HBV-related diseases;
d) Intrafamilial: father or brother or sister were chronic
HBV carriers;
e) Unknown: not in the above classifications or absence of
data.
Serology assays
The presence of the antibodies, anti-HBc and anti-HBs,
and the antigen HBsAg in serum was determined by
enzyme-immunoassays from ABBOTT LABORATORIES
(U.S.A).
Statistical analysis
All data are expressed as means ± standard deviation (SD).
The Student t test was used to analyze the significance of
age. The Pearson x2 was used to test significance of propor-
tions between the ethnic groups when the expected fre-
quencies exceeded 5, otherwise Fisher Exact test was used.
A p value of <0.05 was considered significant. Data analy-
sis was performed with the Epi Info statiscal package [8].
Results
Demographic characteristics
The demographic characteristics of the probands are
shown in Table 1. Sex and age parameters were compara-
ble in the Asian and Western study groups. Both groups
presented a higher proportion of the male gender,
although among the Asian patients the fraction of women
was slightly higher than among the Western counterparts.
Among the Asian probands, all except one were Japanese
descendent. Table 2 shows the demographic characteris-
tics of the family members; sex and age parameters were
comparable in the Asian and Western groups.BMC Family Practice 2004, 5 http://www.biomedcentral.com/1471-2296/5/7
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Ethnic influence on prevalence of HBV infection among 
relatives of chronic HBV carriers
Table 3 summarizes data collected from the patients;
notable differences exist in the prevalence of anti-HBc and
HBsAg among Asian and Western relatives from chronic
hepatitis B patients. Positivity for anti-HBc was higher
among Asian (59.3%) than among Western (36.8%) rela-
tives (p < 0.0001). Also, HBsAg-positive serum was found
in 28.4% and 9.9% of the Asian and Western relatives,
respectively (p < 0.0001).
Comparing Asian and Western family members that
entered in contact with hepatitis B virus, more Asians pre-
sented HBsAg positive. On the other hand, more Western
relatives seroconverted to anti-HBs positive (Table 4).
Familial relation and prevalence of HBsAg
Concerning the degree of familial relation, anti-HBc was
positive in 90% and 57% of the Asian and Western par-
ents (p = 0.0432) and in 97% and 33% of the Asian and
Western brothers (p = 0.0001), respectively. HBsAg was
more frequent among the Asian (66%) than among the
Western (15%) mothers (p = 0.0260) and, even more so,
among the Asian (81%) than the Western (19%) brothers
(p = 0.0001). Likewise, the progeny of the Asians (28%)
presented more HBsAg than of the Westerns (7%; p =
0.0467).
Mode of HBV transmission to probands
The "mother to child" mode of HBV transmission was the
most important one in the Asian probands; whereas the
"sexual" mode was the predominant known way of trans-
mission in the Western group (p < 0.0001); see Table 6.
Table 1: Demographic characteristics of probands
Variable Probands
Asian Western p
n2 3 3 1
Male 15 (65.2%) 25 (80.6%) 0.3344
Age (mean ± SD) 42.8 ± 10.5 42.9 ± 16.8 0.9120
[probands are HBsAg-positive chronic hepatitis B index cases]
Table 2: Demographic characteristics and consanguinity of relatives
Variable Relatives
Asian Western p
n3 1 3 2 1 1
Male 164 (52%) 97 (46%) 0.8120
Age (mean ± SD) 29.9 ± 18.2 31.3 ± 19.6 0.5833
Consanguinity 237 (76%) 157 (74%) 0.1737
Table 3: Prevalence of anti-HBc, HBsAg and anti-HBs in relatives of CHB probands
Markers Asian (%) Western (%) p
Anti-HBc+ 181/305* 59.3% 77/209** 36.8% <0.0001
HBsAg+ 89/313 28.4% 21/211 9.9% <0.0001
Anti-HBc+/ Anti-HBs+ 80/305* 26.2% 54/209** 25.8% 0.9977
Isolated anti-HBc+ 12/305* 3.9% 2/209** 0.9% 0.0782
* anti-HBc was not done in 8 relatives; ** anti-HBc was not done in 2 relatives.BMC Family Practice 2004, 5 http://www.biomedcentral.com/1471-2296/5/7
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Discussion
The Japanese oversea immigrants have a history exceeding
more than 100 years. Today, there is an estimate of 2.5
million Japanese-descendent people living outside Japan,
of whom 1.3 million are in Brazil and one million in the
United States [9].
Overall, the US population has approximately 0.2% of
HBsAg positive individuals, but figures are different
within ethnic groups. African Americans presented higher
prevalence than Caucasians and Asian Americans even
higher, especially the immigrants from China and
Southeast Asia [10]. In Brazil, data on prevalence of hep-
atitis B among Asian descendents as a comparative study
between different ethnic groups are scarce and not precise.
In the present study, Asian relatives from patients with
chronic hepatitis B (CHB) have shown higher anti-HBc
and HBsAg prevalence than that observed in family mem-
bers of patients from Western origin (Table 3). These
results are very similar to the presented by others and to
the predicted and observed prevalence from the mathe-
matical model developed by Carrilho in 1987 [11-14].
At the "Hospital das Clínicas", research on familial HBV
carriers began in 1971, when Carrilho and collaborators
studied 19 Asian and 26 Western CHB patients and 165
and 186 respective relatives [14]. The latter study found
that, altogether, the prevalence of HBsAg and anti-HBs
was 135/165 (81.8%) in the Japanese and 68/186
(36.5%) in the occidental relatives (p < 0.0001). These
Table 4: Prevalence of anti-HBs and HBsAg among relatives with anti-HBc positive
Markers Asian (%) Western (%) p
HBsAg+ 89/181 49% 21/77 27.2% 0.0018
Anti-HBc+/ Anti-
HBs+
80/181 44% 54/77 70.1% 0.0018
Isolated anti-HBc+ 12/181 6.6% 2/77 2.5% 0.2416
Table 5: Prevalence of anti-HBc, HBsAg and anti-HBs in different familial category
Anti-HBc+ HBsAg+ Anti-HBs+ plus anti-HBc +
Asian n (%) Western n (%) p Asian n (%) Western n (%) p Asian n (%) Western n (%) p
Parents 18/20 (90%) 12/21 (57%) 0.0432 8/20 (40%) 3/21 (14%) 0.1323 10/20 (50%) 9/21 (43%) 0.8845
Mothers 9/9 (100%) 7/13 (54%) 0.0941 6/9 (66%) 2/13 (15%) 0.0260 3/9 (33%) 5/13 (38%) 1.0000
Fathers 9/11 (82%) 5/8 (62%) 0.6026 2/11 (18%) 1/8 (12%) 1.0000 7/11 (64%) 4/8 (50%) 0.6576
Brothers/
Sisters
58/60 (97%) 14/42 (33%) <0.0001 49/60 (81%) 8/42 (19%) <0.0001 5/60 (8.3%) 6/42 (14%) 0.3534
Sons/
Daughters
10/29* (31%) 12/52*** (23%) 0.3975 9/32 (28%) 5/54 (7%) 0.0467 0/29* (0%) 7/52*** (13%) 0.0460
Spouses 15/17 (88%) 18/30 (60%) 0.0888 0/17 (0%) 1/30 (3%) 1.0000 14/17 (82%) 16/30 (53%) 0.0942
Others 80/179** (45%) 21/64 (33%) 0.1317 23/184 (12%) 4/64 (6%) 0.2502 51/179** (28%) 16/64 (25%) 0.787
*anti-HBc was not done in 3 relatives, ** anti-HBc was not done in 5 relatives, ***anti-HBc was not done in 2 relatives.
Table 6: Transmission mode of HBV among the probands
Mode Asian Western p =
Probably mother to child 03 03
Mother to child * 12 02 *0.0001
Sexual (horizontal)* 0 11
Intrafamiliar 02 03
Unknown 06 12
Total 23 31BMC Family Practice 2004, 5 http://www.biomedcentral.com/1471-2296/5/7
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data are similar with those of the present study which, in
turn, may also be confirmed by the mathematical model
described by Carrilho [14].
It is noticeable in the present surveillance that 110 cases
of HBsAg-positive individuals – the majority of Asian ori-
gin (Table 3) – were identified, whom otherwise would
not have been diagnosed. Further study comparing the
natural course of chronic hepatitis B in these populations
is needed to assess the benefit of early detection of the
disease.
The findings of a greater prevalence of HBsAg among the
Asian families and, for the Western equivalents, a higher
prevalence of anti-HBs suggest the longer state as chronic
carriers for the Asians (Table 4). This may be due to the
age of acquisition of the disease, which may influence the
prognosis [15]. Children infected by vertical route
(mother to child) may have greater tolerance to HBV with
less hepatic damage, but greater prevalence of the chronic
stage [16]. In fact, when we analyzed the mode of trans-
mission of HBV in the proband groups (Table 6), it was
observed that "mother to child" transmission was greater
among the Asian patients and "sexual" transmission
among the Western ones. Yet, it is important to mention
that notable differences exist in the prevalence of acute
flares of hepatitis in Asian and Western patients [17].
Studies in patients with CHB have shown more serologi-
cal fluctuation in Asians than in patients in the United
States [17]. In a study with 224 HBeAg positive Asian
patients, flares of disease activity occurred in 40% but,
unlike observed for the Western counterparts, this seldom
led to seroconversion or to a sustained virologic response
[17], what is in agreement with our results. The differ-
ences in the natural history of the infection in Asian and
Western patients get particularly relevant when deciding
on the need of antiviral treatment.
The marker anti-HBc was more frequent among Asian par-
ents and brothers and the HBsAg, in turn, was more so in
Asian mothers, brothers and sons (Table 5). These differ-
ences are significant and suggest, specially for the Asian
subjects, that vertical or peri-natal transmission from
mothers are the most significant way of acquiring HBV
infection. The importance of familial screening for hepa-
titis B among the brothers and sisters of the Asian
probands is highly endorsed by the finding of 81% HBsAg
positive among their brotherhood.
While anti-HBc is the principal marker for HBV preva-
lence study in any population, anti-HBs is the hallmark of
immunity conferred by vaccination or recovery from HBV
infection. In the present study, for economical reasons,
anti-HBs was checked only in those who were anti-HBc
positive, thus investigating only the recovery cases. Since
extended hepatitis B vaccine program was introduced in
low prevalence areas in Brazil only in 1998 and vaccine
was available for risk groups only, it remains important to
evaluate the vaccine coverage in those areas.
In conclusion, Asian relatives from chronic HBV carriers
have presented a greater prevalence of HBV markers when
compared to Western equivalents. More Asian family
members were HBsAg positive while more Western rela-
tives presented anti-HBc and anti-HBs positive. Consider-
ing that hepatitis B can be asymptomatic, the present
results emphasize the importance of screening the fami-
lies of the CHB carriers, increasing the chances of a better
treatment outcome and helping to halt the spread of this
infectious disease.
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